Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).

Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A
Ann Rheum Dis. 2001 60 Suppl 3: iii2-5

PMID: 11890647 · PMCID: PMC1766671 · DOI:10.1136/ard.60.90003.iii2

TNF blocking agents have proved to be effective DMARDs and they have been a major advance in the treatment of RA. Their use is expanding to other rheumatic diseases. However, rare to uncommon and unexpected toxicities have been found and others may yet be found during their use. Studies in selected areas of efficacy, toxicity, and general use of TNF blocking agents are needed to help further define the most appropriate use of these agents. Use of these drugs will require doctors experienced in the diagnosis, treatment, and assessment of RA and other rheumatic diseases. These doctors will need to make long term observations of efficacy and toxicity. Further considerations which must be made when using TNF blocking agents in this disease include the cost and a recognition that data in subgroups are still being acquired. It is hoped that this statement, which is based upon the best evidence available at the time of its creation, and modified by expert opinion, will facilitate the optimal use of these agents for our patients with RA and other rheumatic diseases.

MeSH Terms (15)

Antibodies, Monoclonal Antirheumatic Agents Arthritis, Rheumatoid Contraindications Controlled Clinical Trials as Topic Female Humans Male Meta-Analysis as Topic Methotrexate Pregnancy Randomized Controlled Trials as Topic Recombinant Fusion Proteins Rheumatic Diseases Tumor Necrosis Factor-alpha

Connections (1)

This publication is referenced by other Labnodes entities: